Valuation: Satellos Bioscience Inc.

Market Cap 20Cr 17Cr 16Cr 15Cr 28Cr 1.9TCr 29Cr 192.16Cr 75Cr 936.57Cr 75Cr 73Cr 3.22TCr P/E 2026 *
-5.49x
P/E 2027 * -5.85x
Enterprise Value 11Cr 9.24Cr 8.53Cr 7.88Cr 15Cr 1.01TCr 15Cr 101.88Cr 40Cr 496.56Cr 40Cr 39Cr 1.71TCr EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
93.51%
Yield 2026 *
-
Yield 2027 * -
1 day+1.88%
1 week+24.01%
Current month+26.92%
1 month+68.70%
3 months+49.50%
6 months+35.03%
Current year+70.83%
1 week 10.86
Extreme 10.86
14.15
1 month 7.76
Extreme 7.76
14.15
Current year 7.67
Extreme 7.67
18.98
1 year 6.36
Extreme 6.36
18.98
3 years 3.48
Extreme 3.48
18.98
5 years 2.58
Extreme 2.58
22.8
10 years 2.58
Extreme 2.58
22.8
Manager TitleAgeSince
Chief Executive Officer 70 01/03/2018
Chief Tech/Sci/R&D Officer - 01/05/2018
Director of Finance/CFO - 01/09/2023
Director TitleAgeSince
Director/Board Member 76 29/06/2023
Chairman 59 01/07/2018
Director/Board Member 56 14/11/2025
Date Insider Type Main position Quantity % Market Cap.
18/06Buy

Director

15,000 0.0720%
07/04Option

Founder

1,08,630 0.7027%
07/04Buy

Director

5,500 0.0356%
Change 5-day change 1-year change 3-year change Capi.($)
+1.88%+24.01%+94.40%+139.89% 20Cr
+1.84%-0.66%+59.82%+92.96% 5.49TCr
-4.14%-8.06%+58.96%+118.67% 5.46TCr
-2.24%+3.59%+17.75%+477.47% 2.51TCr
-1.60%-6.21%-18.96%-15.21% 2.31TCr
+2.43%+1.06%+42.44%-1.27% 1.99TCr
-3.19%0.00%+35.60%-26.98% 1.75TCr
-6.84%+2.18%+195.12%+357.18% 1.65TCr
+8.74%+3.51%+51.91%+726.40% 1.57TCr
-1.05%+1.16%+25.95%+194.27% 1.42TCr
Average -0.42%+2.15%+56.30%+206.34% 2.42TCr
Weighted average by Cap. -0.89%-1.43%+51.30%+177.11%

Financials

2026 *2027 *
Net sales - -
Net income -4.83Cr -4.23Cr -3.9Cr -3.6Cr -6.83Cr -460.87Cr -6.95Cr -47Cr -18Cr -227.04Cr -18Cr -18Cr -780.52Cr -5.66Cr -4.95Cr -4.56Cr -4.22Cr -8Cr -539.5Cr -8.13Cr -55Cr -21Cr -265.78Cr -21Cr -21Cr -913.68Cr
Net Debt -9.36Cr -8.19Cr -7.56Cr -6.98Cr -13Cr -893.18Cr -13Cr -90Cr -35Cr -440.01Cr -35Cr -34Cr -1.51TCr -11Cr -9.74Cr -8.98Cr -8.3Cr -16Cr -1.06TCr -16Cr -107.34Cr -42Cr -523.17Cr -42Cr -41Cr -1.8TCr
Logo Satellos Bioscience Inc.
Satellos Bioscience Inc. is a Canada-based clinical-stage drug development company. The Company is focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Through its research, the Company has developed SAT-3247, a first-of-its-kind, orally administered small molecule drug designed to address deficits in muscle repair and regeneration. SAT-3247 targets AAK1, a key protein that has identified as capable of replacing the signal normally provided by dystrophin in muscle stem cells to effect repair and regeneration. It is also leveraging its proprietary discovery platform MyoReGenX to identify additional muscle diseases or injury conditions where restoring muscle repair and regeneration may have therapeutic benefit and represent future clinical development opportunities. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process.
Employees
20
Date Price Change Volume
10/26/10 CA$13.53 +1.88% 26,751
09/26/09 CA$13.28 +5.23% 91,570
08/26/08 CA$12.62 +9.26% 2,19,239
07/26/07 CA$11.55 -0.09% 11,729
06/26/06 CA$11.56 +5.96% 13,838
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
13.53CAD
Average target price
17.67CAD
Spread / Average Target
+30.57%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MSCL Stock